Company news

Pfizer, Inc. news in 2025

Pfizer, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Flagship Pioneering and Repertoire® Immune Medicines Announce Agreement to Identify T Cell-Targeted Immune Medicines for Prostate Cancer Under Strategic Partnership with Pfizer

December 22, 2025

New York State's 2025 Emerging Technology Advisory Board Releases Final Report to Boost Biotech Innovation, Commercialization and Public Health Impact

December 19, 2025

Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts

December 18, 2025

PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

December 17, 2025

Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance

December 16, 2025

Pfizer Declares First-Quarter 2026 Dividend

December 12, 2025

TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer

December 10, 2025

Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma

December 9, 2025

HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors

December 6, 2025

Bio/Pharmaceutical Outsourcing Report, October 2025 - Pfizer and Roche Place $10 Billion Bets on Obesity and Liver Disease Therapies as Trump Tightens Grip on Drug Pricing and Manufacturing

December 4, 2025

Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance

December 1, 2025

RVL Pharmaceuticals Announces Leadership Appointments to Accelerate Next Phase of Growth and Commercial Momentum

November 24, 2025

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

November 21, 2025

U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer

November 21, 2025

BMO Launches New CDRs With Exposure to U.S. Stocks Including Apple, Intel, Mastercard, Pfizer and Visa

November 20, 2025

Nona Biosciences and Pfizer Announce Strategic Research Collaboration to Accelerate Antibody Discovery

November 19, 2025

Pfizer Completes Acquisition of Metsera

November 13, 2025

Olema Oncology Reports Third Quarter 2025 Financial and Operating Results

November 10, 2025

Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer

November 7, 2025

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

November 6, 2025

Accipiter Biosciences Emerges from Stealth with $12.7 Million in Seed Financing to Deliver de novo Protein Therapies for Complex Diseases

November 6, 2025

Pfizer Responds to Delaware Chancery Court Ruling

November 5, 2025

Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance

November 4, 2025

Pfizer Files Federal Antitrust Claims in Second Lawsuit Against Metsera, its Controlling Stockholders and Novo Nordisk

November 3, 2025

Pfizer Files Lawsuit Against Metsera and its Directors and Novo Nordisk for Breach of Merger Agreement

October 31, 2025

Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition

October 31, 2025

Pfizer Addresses Proposal for Metsera

October 30, 2025

Pfizer Whistleblower's Story Unveiled: Becky McClain's "Exposed" Memoir Hits Shelves October 28

October 28, 2025

Pfizer and BioNTech Receive Health Sciences Authority Approval for SARS-CoV-2 Sublineage LP.8.1-Adapted Monovalent COVID-19 Vaccine in Singapore

October 24, 2025

XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer

October 19, 2025

Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer

October 19, 2025

PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer

October 18, 2025

ViiV Healthcare announces 96-week data reaffirming Dovato is as effective as Biktarvy in maintaining virological suppression of HIV-1 with significantly less weight gain

October 17, 2025

Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025

October 13, 2025

Pfizer Declares Fourth-Quarter 2025 Dividend

October 9, 2025

Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance

August 5, 2025

Pfizer Completes Licensing Agreement with 3SBio

July 24, 2025

Calls in 2025

Decks in 2025